Gastritis Market is projected to reach USD 3.91 billion by 2034

The global Gastritis Market was valued at USD 2.34 billion in 2024 and is projected to reach USD 3.91 billion by 2034, growing at a CAGR of 5.3% during the forecast period (2025-2034). Growth is driven by rising global prevalence of Helicobacter pylori (H. pylori) infection, increasing NSAID-related gastric inflammation, rising alcohol consumption, expanding geriatric populations, and the increasing availability of advanced diagnostic tests and effective eradication therapies.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71141

Gastritis refers to acute or chronic inflammation of the stomach lining caused by infectious, autoimmune, chemical, or lifestyle-related factors. While acute gastritis often resolves with supportive care, chronic untreated gastritis can progress to peptic ulcers, gastrointestinal bleeding, or gastric cancer, underscoring the importance of early detection and treatment.

Key Market Highlights
• 2024 Market Size: USD 2.34 billion
• 2034 Forecast: USD 3.91 billion
• CAGR (2025-2034): 5.3%
• Largest Segment: H. pylori eradication therapy
• Fastest-Growing Segment: Diagnostic testing (urea breath test, stool antigen test)

Epidemiology & Clinical Insights
1. Global Burden
• H. pylori infects ~50% of the global population, making it the leading cause of chronic gastritis.
• NSAID-induced gastritis is highly prevalent in older adults.
• Autoimmune gastritis is increasingly identified due to improved diagnostics.
2. Types of Gastritis
• Acute gastritis: Usually caused by alcohol, stress, NSAIDs, or infections.
• Chronic gastritis: Primarily due to H. pylori, autoimmune disorders, or long-term irritants.
• Atrophic gastritis: Associated with increased gastric cancer risk.
3. Symptoms
• Epigastric pain
• Bloating
• Nausea/vomiting
• Indigestion
• Loss of appetite
4. Diagnostic Tools
• Endoscopy
• Urea breath test
• Stool antigen test
• Serology
• Gastric biopsy
• AI-enhanced endoscopic imaging

Market Growth Drivers
1. High Prevalence of H. pylori
Major driver of chronic gastritis requiring long-term treatment and follow-up.
2. Growing Use of NSAIDs & Aspirin
Commonly used in cardiovascular and pain management - increasing risk of gastritis.
3. Advancements in Diagnostic Testing
Non-invasive tests (UBT, stool antigen) widely adopted.
4. Development of Targeted Therapies
Dual and triple antibiotic therapies, acid suppression drugs, and bismuth-based regimens.
5. Expansion of Endoscopic Services
Early diagnosis and monitoring of gastritis and complications.

Market Restraints
• Rising antibiotic resistance reducing H. pylori eradication success
• Side effects of long-term proton pump inhibitor (PPI) usage
• Limited awareness in underserved regions
• Recurrent infections requiring repeat treatment

Market Opportunities
1. Novel H. pylori Eradication Agents
Next-generation antibiotics and antimicrobial peptides.
2. Probiotics & Microbiome Therapies
Adjunctive therapy to improve eradication rates and reduce dysbiosis.
3. AI-Assisted Diagnostic Endoscopy
Automated detection of gastritis, atrophy, and early gastric cancer.
4. Vaccines Against H. pylori (In Development)
Potential long-term preventive solution.
5. Personalized Medicine
Genotype-based therapy selection to overcome antibiotic resistance.

Segmentation Overview
By Type
• Acute gastritis
• Chronic gastritis
• Atrophic gastritis

By Cause
• H. pylori infection
• NSAID-induced
• Autoimmune
• Alcohol-related
• Stress-induced
• Others

By Treatment
• Antibiotic therapy (dual/triple/quadruple regimens)
• Proton pump inhibitors (PPIs)
• H2 blockers
• Antacids
• Probiotics
• Dietary/lifestyle interventions

By Diagnostic Method
• Upper GI endoscopy
• Urea breath test
• Stool antigen test
• Serological tests
• Biopsy

By End User
• Hospitals
• Gastroenterology clinics
• Diagnostic centers
• Retail & online pharmacies

Explore Full Report here: https://exactitudeconsultancy.com/reports/71141/gastritis-market

Regional Insights
North America - Largest Market
High NSAID use, advanced diagnostics adoption, and strong focus on early GI disease detection.
Europe - Robust Diagnostic Infrastructure
Leading countries include Germany, Italy, France, and the UK.
Asia Pacific - Fastest Growing
Highest global burden of H. pylori infection, large population, and rapid expansion of GI healthcare services.
Latin America - Emerging
Improved access to diagnostics and increasing awareness of H. pylori-related complications.
Middle East & Africa - Developing
Gradual growth due to wider availability of non-invasive tests.

Competitive Landscape
Key companies active in the gastritis therapeutics and diagnostics market include:
• Takeda Pharmaceutical
• AstraZeneca
• Bayer AG
• Pfizer
• Dr. Reddy's Laboratories
• Abbott
• GlaxoSmithKline
• Cadila Pharmaceuticals
• Eisai Co. Ltd.
• Sanofi
Focus areas include improved antibiotic regimens, acid suppression therapies, diagnostics, and microbiome-based products.

Recent Market Developments
• Increasing adoption of vonoprazan-based triple therapies
• Rising interest in probiotic adjunct therapy for H. pylori
• AI-powered endoscopic imaging rapidly improving diagnostic accuracy
• Growing clinical emphasis on managing atrophic gastritis to prevent gastric cancer

Future Outlook (2025-2034)
The Gastritis Market is expected to grow steadily as:
• H. pylori continues to drive global disease burden
• Non-invasive diagnostics become widespread
• Therapeutic regimens evolve to combat antibiotic resistance
• Probiotics and combination therapies gain traction
• GI imaging and AI improve early detection
By 2034, the market is projected to reach USD 3.91 billion, supported by strong demand for improved diagnostics and effective eradication therapies.

This report is also available in the following languages : Japanese (胃炎市場), Korean (위염 시장), Chinese (胃炎市场), French (Marché de la gastrite), German (Gastritis-Markt), and Italian (Mercato della gastrite), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71141

Our More Reports:

Helicobacter Pylori Infections Market
https://exactitudeconsultancy.com/reports/71739/helicobacter-pylori-infections-market

Helicobacter Pylori Market
https://exactitudeconsultancy.com/reports/72885/helicobacter-pylori-market

Gastritis Treatment Market
https://exactitudeconsultancy.com/reports/51821/gastritis-treatment-market

Functional Dyspepsia Market
https://exactitudeconsultancy.com/reports/71114/functional-dyspepsia-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.